Structural study points the way to better malaria drugs
January 23, 2024
January 23, 2024
ITHACA, New York, Jan. 23 -- Cornell University issued the following news:
Structural insights into a potent antimalarial drug candidate's interaction with a malaria parasite have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.
The antimalarial molecule, TDI-8304, is one of a new class of experimental therapeutics that targets the proteasome, an essential multiprotein complex . . .
Structural insights into a potent antimalarial drug candidate's interaction with a malaria parasite have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.
The antimalarial molecule, TDI-8304, is one of a new class of experimental therapeutics that targets the proteasome, an essential multiprotein complex . . .